Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03781063 |
|
Recruitment Status :
Active, not recruiting
First Posted : December 19, 2018
Last Update Posted : April 18, 2024
|
Sponsor:
Sermonix Pharmaceuticals Inc.
Collaborator:
Linical Accelovance Group
Information provided by (Responsible Party):
Sermonix Pharmaceuticals Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | December 2024 |
| Estimated Study Completion Date : | December 2024 |